IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Study Summary

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Conditions

Metastatic Uveal Melanoma

Interventions / Drugs

IDE196 Crizotinib Pembrolizumab Ipilimumab Nivolumab Dacarbazine

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment420 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812118+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.